MIRM
Mirum Pharmaceuticals, Inc.
Price Chart
Latest Quote
$114.97
+3.90 (+3.51%)
Current Price
| Previous Close | $111.07 |
| Open | $111.51 |
| Day High | $115.87 |
| Day Low | $109.17 |
| Volume | 969,097 |
Stock Information
| Shares Outstanding | 60.98M |
| Total Debt | $323.78M |
| Cash Equivalents | $386.26M |
| Revenue | $569.61M |
| Net Income | $-798.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.01B |
| EPS (TTM) | $-13.60 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.71B |
| Sales | $569.61M |
| Income | $-798.84M |
| Book/sh | $3.98 |
| Cash/sh | $6.33 |
| Employees | 418 |
Financial Ratios
| Quick Ratio | 1.90 |
| Current Ratio | 2.09 |
| Debt/Eq | 133.52 |
Returns & Margins
| ROA | -5.94% |
| ROE | -335.82% |
| Gross Margin | 81.39% |
| Operating Margin | -39.51% |
| Profit Margin | -140.24% |
Ownership
| Insider Ownership | 1.40% |
| Institutional Ownership | 114.42% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1313.94 |
| P/S | 12.31 |
| P/B | 28.89 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $145.36 |
Technical Indicators
| SMA20 | $99.61 |
| SMA50 | $99.49 |
| SMA200 | $86.71 |
| RSI | 93.68 |
| ATR | 4.4639 |
| Shares Float | 52.46M |
| Short Float | 14.11% |
| Short Ratio | 5.18 |
| Volatility | 0.51 |
| Rel Volume | 1.13 |
Performance History
| Week | +13.22% |
| Month | +16.58% |
| Quarter | +30.83% |
| 6 Months | +47.89% |
| YTD | +47.27% |
| Year | +128.68% |
| 3 Years | +317.31% |
| 5 Years | +538.37% |
| 10 Years | +770.33% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $114.97 | 969,097 |
| 2026-06-23 | $111.07 | 1,129,100 |
| 2026-06-22 | $107.77 | 1,207,200 |
| 2026-06-18 | $107.13 | 1,576,800 |
| 2026-06-17 | $102.04 | 1,966,100 |
| 2026-06-16 | $101.55 | 868,700 |
| 2026-06-15 | $101.00 | 832,600 |
| 2026-06-12 | $99.35 | 553,600 |
| 2026-06-11 | $99.54 | 687,800 |
| 2026-06-10 | $94.00 | 471,800 |
| 2026-06-09 | $95.48 | 694,200 |
| 2026-06-08 | $93.58 | 473,300 |
| 2026-06-05 | $93.48 | 585,300 |
| 2026-06-04 | $92.49 | 697,700 |
| 2026-06-03 | $91.83 | 619,800 |
| 2026-06-02 | $92.17 | 661,200 |
| 2026-06-01 | $96.33 | 599,100 |
| 2026-05-29 | $101.50 | 1,370,000 |
| 2026-05-28 | $99.60 | 536,300 |
| 2026-05-27 | $97.33 | 668,800 |
| 2026-05-26 | $98.90 | 704,600 |
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
đ° Latest News
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Zacks âĸ 2026-06-17T10:47:00Z
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Zacks âĸ 2026-06-15T14:43:00Z
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
Zacks âĸ 2026-06-05T15:30:24Z
Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress
Insider Monkey âĸ 2026-06-04T09:06:50Z
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
Investing.com âĸ 2026-05-28T20:27:17ZMirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
MarketBeat âĸ 2026-05-27T11:09:10Z
Mirumâs US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM)
Simply Wall St. âĸ 2026-05-25T16:10:05Z
Mirum Pharma: A Rare Disease Growth Story to Watch
MarketBeat âĸ 2026-05-20T16:35:00Z
Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 Loss - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-05-07T22:17:31Z
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
Zacks âĸ 2026-05-07T16:04:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $100,240,000 | $81,643,000 | $47,039,000 | $12,374,000 |
| Cost Of Revenue | $100,240,000 | $81,643,000 | $47,039,000 | $12,374,000 |
| Total Revenue | $521,312,000 | $336,888,000 | $186,374,000 | $77,062,000 |
| Operating Revenue | $521,312,000 | $336,888,000 | $186,374,000 | $77,062,000 |
| Expenses | ||||
| Interest Expense | $14,389,000 | $14,311,000 | $15,105,000 | $15,979,000 |
| Total Expenses | $543,448,000 | $424,494,000 | $295,528,000 | $208,282,000 |
| Other Income Expense | $2,371,000 | $1,213,000 | $-51,900,000 | $1,271,000 |
| Other Non Operating Income Expenses | $2,371,000 | $1,213,000 | $-2,824,000 | $365,000 |
| Net Non Operating Interest Income Expense | $-1,662,000 | $-519,000 | $-1,370,000 | $-12,122,000 |
| Interest Expense Non Operating | $14,389,000 | $14,311,000 | $15,105,000 | $15,979,000 |
| Operating Expense | $443,208,000 | $342,851,000 | $248,489,000 | $195,908,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-23,363,000 | $-87,942,000 | $-163,415,000 | $-135,665,000 |
| Net Interest Income | $-1,662,000 | $-519,000 | $-1,370,000 | $-12,122,000 |
| Interest Income | $12,727,000 | $13,792,000 | $13,735,000 | $3,857,000 |
| Normalized Income | $-23,363,000 | $-87,942,000 | $-124,644,960 | $-136,530,139 |
| Net Income From Continuing And Discontinued Operation | $-23,363,000 | $-87,942,000 | $-163,415,000 | $-135,665,000 |
| Total Operating Income As Reported | $-22,136,000 | $-87,606,000 | $-109,154,000 | $-131,220,000 |
| Net Income Common Stockholders | $-23,363,000 | $-87,942,000 | $-163,415,000 | $-135,665,000 |
| Net Income | $-23,363,000 | $-87,942,000 | $-163,415,000 | $-135,665,000 |
| Net Income Including Noncontrolling Interests | $-23,363,000 | $-87,942,000 | $-163,415,000 | $-135,665,000 |
| Net Income Continuous Operations | $-23,363,000 | $-87,942,000 | $-163,415,000 | $-135,665,000 |
| Pretax Income | $-21,427,000 | $-86,912,000 | $-162,424,000 | $-142,071,000 |
| Special Income Charges | $0 | $0 | $-49,076,000 | $0 |
| Interest Income Non Operating | $12,727,000 | $13,792,000 | $13,735,000 | $3,857,000 |
| Operating Income | $-22,136,000 | $-87,606,000 | $-109,154,000 | $-131,220,000 |
| Gross Profit | $421,072,000 | $255,245,000 | $139,335,000 | $64,688,000 |
| Average Dilution Earnings | - | $0 | $0 | $-914,000 |
| Per Share | ||||
| Diluted EPS | $-0.47 | $-1.85 | $-3.94 | $-4.02 |
| Basic EPS | $-0.47 | $-1.85 | $-3.94 | $-4.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-10,305,960 | $40,861 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $17,206,000 | $-48,972,000 | $-87,414,000 | $-123,760,000 |
| Total Unusual Items | $0 | $0 | $-49,076,000 | $906,000 |
| Total Unusual Items Excluding Goodwill | $0 | $0 | $-49,076,000 | $906,000 |
| Reconciled Depreciation | $24,244,000 | $23,629,000 | $10,829,000 | $3,238,000 |
| EBITDA (Bullshit earnings) | $17,206,000 | $-48,972,000 | $-136,490,000 | $-122,854,000 |
| EBIT | $-7,038,000 | $-72,601,000 | $-147,319,000 | $-126,092,000 |
| Diluted Average Shares | $50,198,304 | $47,522,594 | $40,885,124 | $33,982,493 |
| Basic Average Shares | $50,198,304 | $47,522,594 | $40,885,124 | $33,839,072 |
| Diluted NI Availto Com Stockholders | $-23,363,000 | $-87,942,000 | $-163,415,000 | $-136,579,000 |
| Tax Provision | $1,936,000 | $1,030,000 | $991,000 | $-6,406,000 |
| Research And Development | $186,178,000 | $140,630,000 | $102,609,000 | $106,842,000 |
| Selling General And Administration | $257,030,000 | $202,221,000 | $145,880,000 | $89,066,000 |
| Other Special Charges | - | - | $49,076,000 | - |
| Gain On Sale Of Security | - | - | - | $906,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $53,769,000 | $-24,179,000 | $-4,255,000 | $83,083,000 |
| Total Assets | $842,813,000 | $670,754,000 | $646,621,000 | $352,906,000 |
| Total Non Current Assets | $293,129,000 | $277,966,000 | $259,080,000 | $162,681,000 |
| Other Non Current Assets | $13,500,000 | $5,807,000 | $4,165,000 | $101,382,000 |
| Goodwill And Other Intangible Assets | $260,921,000 | $249,819,000 | $252,925,000 | $58,954,000 |
| Other Intangible Assets | $260,921,000 | $249,819,000 | $252,925,000 | $58,954,000 |
| Current Assets | $549,684,000 | $392,788,000 | $387,541,000 | $190,225,000 |
| Other Current Assets | $18,140,000 | $11,784,000 | $10,935,000 | $8,947,000 |
| Inventory | $24,887,000 | $22,403,000 | $22,312,000 | $5,565,000 |
| Receivables | $123,330,000 | $78,286,000 | $67,968,000 | $23,994,000 |
| Accounts Receivable | $123,330,000 | $78,286,000 | $67,968,000 | $23,994,000 |
| Cash Cash Equivalents And Short Term Investments | $383,327,000 | $280,315,000 | $286,326,000 | $151,719,000 |
| Cash And Cash Equivalents | $296,683,000 | $222,503,000 | $286,326,000 | $28,003,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $13,114,000 | $85,579,000 | $20,095,000 | - |
| Total Debt | $319,452,000 | $317,763,000 | $308,142,000 | $2,188,000 |
| Long Term Debt And Capital Lease Obligation | $317,313,000 | $316,054,000 | $307,038,000 | $1,257,000 |
| Long Term Debt | $309,797,000 | $308,082,000 | $306,421,000 | - |
| Current Debt And Capital Lease Obligation | $2,139,000 | $1,709,000 | $1,104,000 | $931,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $528,123,000 | $445,114,000 | $397,951,000 | $210,869,000 |
| Total Non Current Liabilities Net Minority Interest | $322,324,000 | $318,563,000 | $310,887,000 | $146,140,000 |
| Other Non Current Liabilities | $5,011,000 | $2,509,000 | $3,849,000 | $4,532,000 |
| Current Liabilities | $205,799,000 | $126,551,000 | $87,064,000 | $64,729,000 |
| Payables And Accrued Expenses | $156,384,000 | $92,594,000 | $65,021,000 | $48,048,000 |
| Interest Payable | $2,108,000 | $2,108,000 | $2,108,000 | $0 |
| Payables | $25,822,000 | $23,979,000 | $14,132,000 | $11,146,000 |
| Other Payable | $16,208,000 | $9,361,000 | $6,716,000 | $2,456,000 |
| Accounts Payable | $9,614,000 | $14,618,000 | $7,416,000 | $8,690,000 |
| Non Current Deferred Liabilities | - | - | $0 | $140,351,000 |
| Other Current Liabilities | - | - | - | $1,090,000 |
| Equity | ||||
| Common Stock Equity | $314,690,000 | $225,640,000 | $248,670,000 | $142,037,000 |
| Total Equity Gross Minority Interest | $314,690,000 | $225,640,000 | $248,670,000 | $142,037,000 |
| Stockholders Equity | $314,690,000 | $225,640,000 | $248,670,000 | $142,037,000 |
| Gains Losses Not Affecting Retained Earnings | $351,000 | $-373,000 | $1,644,000 | $-217,000 |
| Other Equity Adjustments | $351,000 | $-373,000 | $1,644,000 | $-217,000 |
| Retained Earnings | $-667,544,000 | $-644,181,000 | $-556,239,000 | $-392,824,000 |
| Other | ||||
| Ordinary Shares Number | $51,896,391 | $48,338,096 | $46,723,143 | $36,956,345 |
| Share Issued | $51,896,391 | $48,338,096 | $46,723,143 | $36,956,345 |
| Tangible Book Value | $53,769,000 | $-24,179,000 | $-4,255,000 | $83,083,000 |
| Invested Capital | $624,487,000 | $533,722,000 | $555,091,000 | $142,037,000 |
| Working Capital | $343,885,000 | $266,237,000 | $300,477,000 | $125,496,000 |
| Capital Lease Obligations | $9,655,000 | $9,681,000 | $1,721,000 | $2,188,000 |
| Total Capitalization | $624,487,000 | $533,722,000 | $555,091,000 | $142,037,000 |
| Additional Paid In Capital | $981,878,000 | $870,189,000 | $803,260,000 | $535,074,000 |
| Capital Stock | $5,000 | $5,000 | $5,000 | $4,000 |
| Common Stock | $5,000 | $5,000 | $5,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $7,516,000 | $7,972,000 | $617,000 | $1,257,000 |
| Current Capital Lease Obligation | $2,139,000 | $1,709,000 | $1,104,000 | $931,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $47,276,000 | $32,248,000 | $20,939,000 | $14,660,000 |
| Current Accrued Expenses | $130,562,000 | $68,615,000 | $50,889,000 | $36,902,000 |
| Investments And Advances | $8,105,000 | $12,526,000 | $0 | $0 |
| Net PPE | $10,603,000 | $9,814,000 | $1,990,000 | $2,345,000 |
| Gross PPE | $10,603,000 | $9,814,000 | $1,990,000 | $2,345,000 |
| Other Properties | $10,603,000 | $9,814,000 | $1,990,000 | $914,000 |
| Finished Goods | $3,516,000 | $3,284,000 | $9,441,000 | $214,000 |
| Work In Process | $18,473,000 | $16,089,000 | $9,873,000 | $5,351,000 |
| Raw Materials | $2,898,000 | $3,030,000 | $2,998,000 | $0 |
| Other Short Term Investments | $86,644,000 | $57,812,000 | $0 | $123,716,000 |
| Non Current Deferred Revenue | - | - | $0 | $140,351,000 |
| Buildings And Improvements | - | - | $1,284,000 | $1,431,000 |
| Properties | - | - | $0 | $0 |
| Treasury Shares Number | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $54,873,000 | $-10,668,000 | $-91,053,000 | $-120,414,000 |
| Operating Activities | ||||
| Operating Cash Flow | $55,827,000 | $10,325,000 | $-70,944,000 | $-120,136,000 |
| Cash Flow From Continuing Operating Activities | $55,827,000 | $10,325,000 | $-70,944,000 | $-120,136,000 |
| Operating Gains Losses | $-1,720,000 | $-1,231,000 | $1,764,000 | $-906,000 |
| Investing Activities | ||||
| Capital Expenditure | $-954,000 | $-20,993,000 | $-20,109,000 | $-278,000 |
| Investing Cash Flow | $-23,954,000 | $-90,125,000 | $-107,200,000 | $7,700,000 |
| Cash Flow From Continuing Investing Activities | $-23,954,000 | $-90,125,000 | $-107,200,000 | $7,700,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $216,684,000 | $107,367,000 |
| Financing Cash Flow | $40,142,000 | $17,699,000 | $336,600,000 | $109,087,000 |
| Cash Flow From Continuing Financing Activities | $40,142,000 | $17,699,000 | $336,600,000 | $109,087,000 |
| Net Common Stock Issuance | $0 | $0 | $216,684,000 | $107,367,000 |
| Common Stock Issuance | $0 | $0 | $216,684,000 | $107,367,000 |
| Net Other Financing Charges | - | - | $-195,858,000 | $-5,552,000 |
| Cash Dividends Paid | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $0 | $0 | $305,304,000 | $0 |
| Interest Paid Supplemental Data | $12,650,000 | $12,650,000 | $6,817,000 | $0 |
| Income Tax Paid Supplemental Data | $2,157,000 | $1,004,000 | $125,000 | $0 |
| End Cash Position | $298,165,000 | $222,928,000 | $286,326,000 | $128,003,000 |
| Beginning Cash Position | $222,928,000 | $286,326,000 | $128,003,000 | $131,340,000 |
| Effect Of Exchange Rate Changes | $3,222,000 | $-1,297,000 | $-133,000 | $12,000 |
| Changes In Cash | $72,015,000 | $-62,101,000 | $158,456,000 | $-3,349,000 |
| Proceeds From Stock Option Exercised | $40,142,000 | $17,699,000 | $10,470,000 | $7,272,000 |
| Net Issuance Payments Of Debt | $0 | $0 | $305,304,000 | $0 |
| Net Long Term Debt Issuance | $0 | $0 | $305,304,000 | $0 |
| Long Term Debt Issuance | $0 | $0 | $305,304,000 | $0 |
| Net Investment Purchase And Sale | $-23,000,000 | $-69,132,000 | $125,671,000 | $7,978,000 |
| Sale Of Investment | $74,425,000 | $19,894,000 | $153,000,000 | $140,300,000 |
| Purchase Of Investment | $-97,425,000 | $-89,026,000 | $-27,329,000 | $-132,322,000 |
| Net Business Purchase And Sale | $0 | $0 | $-212,762,000 | $0 |
| Purchase Of Business | $0 | $0 | $-212,762,000 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-20,000,000 | $-20,000,000 | $0 |
| Purchase Of Intangibles | $0 | $-20,000,000 | $-20,000,000 | $0 |
| Net PPE Purchase And Sale | $-954,000 | $-993,000 | $-109,000 | $-278,000 |
| Purchase Of PPE | $-954,000 | $-993,000 | $-109,000 | $-278,000 |
| Change In Working Capital | $-19,715,000 | $22,591,000 | $-19,221,000 | $-21,050,000 |
| Change In Other Current Liabilities | $-1,896,000 | $-782,000 | $-940,000 | $-711,000 |
| Change In Other Current Assets | $-5,663,000 | $-1,498,000 | $-511,000 | $-127,000 |
| Change In Payables And Accrued Expense | $50,103,000 | $40,312,000 | $30,778,000 | $7,639,000 |
| Change In Payable | $50,103,000 | $40,312,000 | $30,778,000 | $7,639,000 |
| Change In Account Payable | $50,103,000 | $40,312,000 | $30,778,000 | $7,639,000 |
| Change In Prepaid Assets | $-5,756,000 | $-849,000 | $-3,600,000 | $-3,676,000 |
| Change In Inventory | $-8,448,000 | $-3,166,000 | $-974,000 | $-3,448,000 |
| Change In Receivables | $-48,055,000 | $-11,426,000 | $-43,974,000 | $-20,727,000 |
| Changes In Account Receivables | $-48,055,000 | $-11,426,000 | $-43,974,000 | $-20,727,000 |
| Other Non Cash Items | $2,068,000 | $2,220,000 | $54,819,000 | $12,914,000 |
| Stock Based Compensation | $71,424,000 | $48,444,000 | $35,023,000 | $27,007,000 |
| Provisionand Write Offof Assets | $2,889,000 | $2,614,000 | $9,257,000 | $0 |
| Depreciation Amortization Depletion | $24,244,000 | $23,629,000 | $10,829,000 | $3,238,000 |
| Depreciation And Amortization | $24,244,000 | $23,629,000 | $10,829,000 | $3,238,000 |
| Net Foreign Currency Exchange Gain Loss | $-1,720,000 | $-1,231,000 | $1,764,000 | $0 |
| Net Income From Continuing Operations | $-23,363,000 | $-87,942,000 | $-163,415,000 | $-135,665,000 |
| Deferred Tax | - | $0 | $0 | $-6,580,000 |
| Deferred Income Tax | - | $0 | $0 | $-6,580,000 |
| Amortization Of Securities | - | - | $-1,725,000 | $-1,703,000 |
| Depreciation | - | - | - | $3,681,000 |
| Gain Loss On Investment Securities | - | - | - | $-906,000 |
| Interest Paid Cff | - | - | - | - |
Fetched: 2026-06-23